MTCH2

Across TCGA pan-cancer cohorts, MTCH2 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of MTCH2’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where MTCH2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MTCH2 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

STAD, THCA, and LUSC are the cancer types where MTCH2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTCH2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	Female	All	+1.065	<.001	9	view →
THCA	Male	III,IV	−0.501	<.001	9	view →
LUSC	Female	II,III,IV	+1.077	<.001	8	view →
LUAD	Male	All	+0.757	<.001	8	view →
HNSC	Male	All	+0.385	<.001	8	view →
KICH	All	II,III,IV	−0.814	<.001	7	view →
KIRC	Male	All	−0.553	<.001	7	view →
LIHC	Male	All	+0.468	<.001	7	view →
BLCA	All	All	+0.462	.001	7	view →
UCEC	All	II,III,IV	+1.127	<.001	6	view →
BRCA	All	III,IV	+0.675	<.001	6	view →
KIRP	Male	All	−0.456	.004	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

MTCH2–STAD

Open the STAD breakdown →